From ESMO World Congress on Gastrointestinal Cancer 2023:
The addition of ipilimumab to nivolumab does not improve the outcome of patients with inoperable or metastatic squamous cell carcinoma of the anus who have progressed after systemic chemoradiation
Welcome to OncologyPRO – educational and scientific content for ESMO Members. Participants of some ESMO Meetings will have access to the Meeting resources section—limited to the meeting you attended. To gain full access to all the resources on this website, you must be an ESMO Member.
Please sign in using the username and password you created. To ensure a seamless browsing experience, we suggest that you sign in at the start of your visit.